A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

2.3K views

⸱

DOI:

10.3791/61987

⸱

February 4th, 2021

 ,  ,  ,  ,  ,  ,  , 
1Department of Ophthalmology, University Hospital RWTH Aachen, 2Experimental Ophthalmology, University of Geneva, 3Department of Ophthalmology, University Hospitals of Geneva, 4Université de Paris, CNRS, INSERM, UTCBS, Unité des technologies Chimiques et Biologiques pour la Santé, 5Chimie ParisTech, PSL Research University, 6Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 7Division of Medical Biotechnology, Paul-Ehrlich-Institute

In This Article

Summary

We have developed a protocol to transfect primary human pigment epithelial cells by electroporation with the gene encoding pigment epithelium-derived factor (PEDF) using the Sleeping Beauty (SB) transposon system. Successful transfection was demonstrated by quantitative polymerase chain reaction (qPCR), immunoblotting, and enzyme-linked immunosorbent assay (ELISA).

Abstract

Our increasingly aging society leads to a growing incidence of neurodegenerative diseases. So far, the pathological mechanisms are inadequately understood, thus impeding the establishment of defined treatments. Cell-based additive gene therapies for the increased expression of a protective factor are considered as a promising option to medicate neurodegenerative diseases, such as age-related macular degeneration (AMD). We have developed a method for the stable expression of the gene encoding pigment epithelium-derived factor (PEDF), which is characterized as a neuroprotective and anti-angiogenic protein in the nervous system, into the genome of primary human pigment epithelial (PE) cells using the Sleeping Beauty (SB) transposon system. Primary PE cells were isolated from human donor eyes and maintained in culture. After reaching confluence, 1 x 104 cells were suspended in 11 µL of resuspension buffer and combined with 2 µL of a purified solution containing 30 ng of hyperactive SB (SB100X) transposase plasmid and 470 ng of PEDF transposon plasmid. Genetic modification was carried out with a capillary electroporation system using the following parameters: two pulses with a voltage of 1,100 V and a width of 20 ms. Transfected cells were transferred into culture plates containing medium supplemented with fetal bovine serum; antibiotics and antimycotics were added with the first medium exchange. Successful transfection was demonstrated in independently performed experiments. Quantitative polymerase chain reaction (qPCR) showed the increased expression of the PEDF transgene. PEDF secretion was significantly elevated and remained stable, as evaluated by immunoblotting, and quantified by enzyme-linked immunosorbent assay (ELISA). SB100X-mediated transfer allowed for a stable PEDF gene integration into the genome of PE cells and ensured the continuous secretion of PEDF, which is critical for the development of a cell-based gene addition therapy to treat AMD or other retinal degenerative diseases. Moreover, analysis of the integration profile of the PEDF transposon into human PE cells indicated an almost random genomic distribution.

Introduction

Advanced age is described to be the main risk for neurodegenerative diseases. Age-related macular degeneration (AMD), a polygenic disease leading to severe vision loss in patients older than 60 years of age, belongs to the four most common causes of blindness and vision impairment1 and is expected to increase to 288 million people in 20402. Dysfunctions of the retinal pigment epithelium (RPE), a single layer of tightly packed cells located between the choriocapillaris and the retinal photoreceptors, contribute to the pathogenesis of AMD. The RPE fulfills multiple tasks that are essential for a normal retinal function3 and secretes a variety of growth factors and factors essential to maintain the structural integrity of the retina and the choriocapillaris, thereby supporting photoreceptor survival and providing a basis for the circulation and the supply of nutrients.

In healthy eyes, pigment epithelium-derived factor (PEDF) is responsible for balancing the effects of vascular endothelial growth factor (VEGF) and protects neurons against apoptosis, prevents endothelial cell proliferation, and stabilizes the capillary endothelium. A shifted VEGF-to-PEDF ratio is related to ocular neovascularization, which was observed in animal models4,5 as well as in samples of patients with choroidal neovascularization (CNV) due to AMD and proliferative diabetic retinopathy6,7,8,9,10. The enhanced VEGF concentration is the target for the current standard treatment. The anti-VEGF pharmaceuticals bevacizumab, ranibizumab, aflibercept and, most recently, brolucizumab improve visual acuity in about one third of CNV patients or rather stabilize vision in 90% of cases11,12,13. However, the frequent, often monthly, intravitreal injections bear the risk of adverse events14, impair patient compliance, and represent a significant economic burden to healthcare systems15. Moreover, a certain percentage of patients (2%-20%) do not respond or only poorly react to the anti-VEGF therapy16,17,18,19. These negative concomitants necessitate the development of alternative treatments, e.g., intraocular implants, cell and/or gene therapeutic approaches.

Gene therapy has evolved as promising treatment for hereditary and non-hereditary diseases and intends to restore non-functional gene sequences or suppress malfunctioned ones. For polygenic diseases, where identification and replacement of the causative factors is hardly possible, strategies aim for the continuous delivery of a protective factor. In the case of AMD, various additive therapies have been developed, such as the stable expression of endostatin and angiostatin20, the VEGF antagonist soluble fms-like tyrosine kinase-1 (sFLT-1)21,22, the complement regulatory protein cluster of differentiation 59 (CD59)23 or PEDF24,25. The eye, and especially the retina, is an excellent target for a gene-based medication due to the enclosed structure, good accessibility, small size, and immune privilege, thus allowing for a localized delivery of low therapeutic doses and making transplants less susceptible to rejection. Moreover, the eye enables non-invasive monitoring, and the retina can be examined by different imaging techniques.

Viral vectors are, because of their high transduction efficiency, the main vehicle to deliver therapeutic genes into target cells. However, depending on the viral vector used, different adverse reactions have been described, such as immune and inflammatory responses26, mutagenic and oncogenic effects27,28, or dissemination in other tissues29. Practical limitations include a restricted packaging size30 as well as difficulties and costs associated with the production of clinical grade lots31,32. These drawbacks have promoted the further development of non-viral, plasmid-based vectors that are transferred via lipo-/polyplexes, ultrasound or electroporation. However, genomic integration of the transgene into the host genome is usually not promoted with plasmid vectors, thus resulting in a transient expression.

Transposons are naturally occurring DNA fragments that change their position within the genome, a characteristic that has been adopted for gene therapy. Due to an active integration mechanism, transposon-based vector systems allow for a continuous and constant expression of the inserted transgene. The Sleeping Beauty (SB) transposon, reconstituted from an ancient Tc1/mariner-type transposon found in fish33 and further improved by molecular evolution resulting in the hyperactive variant SB100X34, enabled efficient transposition in various primary cells and was used for the phenotypic correction in different disease models35. At present, 13 clinical trials have been initiated using the SB transposon system. The SB100X transposon system consists of two components: the transposon, which comprises the gene of interest flanked by terminal inverted repeats (TIRs), and the transposase, which mobilizes the transposon. Following plasmid DNA delivery to the cells, the transposase binds the TIRs and catalyzes the excision and integration of the transposon into the cell's genome.

We have developed a non-viral cell-based additive therapy for the treatment of neovascular AMD. The approach comprises the electroporation-based insertion of the PEDF gene into primary pigment epithelial (PE) cells by means of the SB100X transposon system36,37,38. The genetic information of the transposase and PEDF are provided on separate plasmids, thereby enabling the adjustment of the ideal SB100X-to-PEDF transposon ratio. Electroporation is performed using a pipette-based capillary transfection system that is characterized by a maximized gap size between the electrodes while minimizing their surface area. The device was shown to achieve excellent transfection rates in a wide range of mammalian cells39,40,41. The small electrode surface area provides a uniform electric field and reduces the various side effects of electrolysis42.

The anti-angiogenic functionality of PEDF secreted by transfected pigment epithelial cells was shown in various in vitro experiments analyzing the sprouting, migration, and apoptosis of human umbilical vein endothelial cells43. In addition, transplantation of PEDF-transfected cells in a rabbit model of corneal neovascularization44 as well as a rat model of CNV43,45,46 showed decline of neovascularization.

Here, we describe a detailed protocol for the stable insertion of the PEDF gene into primary human RPE cells via the SB100X transposon system using a capillary transfection system. The transfected cells were kept in culture for 21 days and subsequently analyzed in terms of PEDF gene expression by quantitative polymerase chain reaction (qPCR) and in terms of PEDF protein secretion by immunoblotting and enzyme-linked immunosorbent assay (ELISA, Figure 1).

Access restricted. Please log in or start a trial to view this content.

Protocol

Human donor eyes were obtained from the Aachen Cornea Bank of the Department of Ophthalmology (University Hospital RWTH Aachen) after obtaining informed consent in accordance with the Declaration of Helsinki protocols. Procedures for the collection and use of human samples have been approved by the institutional ethics committee.

1. Isolation of primary human RPE cells

  1. Lay out sterile protective clothing and gloves. Place a sterile drape under a laminar flow.
  2. Place sterile preparation instruments and other necessary sterile equipment under the laminar flow.
  3. Record the receipt of the eye globes, the beginning of the preparation as well as possible abnormalities. Register donor age, gender, cause of death, and the period between time of death and eye removal.
  4. Place the eye globe in a sterile gauze compress and hold it in one hand.
  5. Separate the anterior segment from the posterior segment by a circumferential cut approximately 3.5 mm posterior to the limbus using a scalpel and an extra fine pointed eye scissor.
  6. After tilting the posterior segment downwards, carefully remove the vitreous and the retina using colibri forceps.
  7. Discreetly rearrange the collapsed RPE/choroidea complex using straight iris forceps and subsequently hold it in position with curved iris forceps.
  8. Fill the posterior eye cup with 1 mL of Dulbecco's Modified Eagle's Medium/Ham's F-12 Nutrient Mixture (DMEM/F12) supplemented with 10% fetal bovine serum (FBS), 80 U/mL penicillin and 80 µg/mL streptomycin (Pen/Strep), and 2.5 µg/mL amphotericin B (AmphoB).
    ​NOTE: Contrary to the isolation of primary RPE cells from pig or bovine eyes36,37, the posterior eye cup doesn't have to be filled and incubated with trypsin.
  9. Harvest the RPE cells by gently brushing the retinal pigment epithelium from the optic nerve toward the limbus with a fire-polished curved glass Pasteur pipette, while fixating the RPE/choroidea complex at the limbus using colibri forceps. Transfer the cell suspension into a Petri dish.
  10. Repeat the steps 1.8 and 1.9 and collect all cells in the Petri dish. Resuspend the cell suspension carefully by pipetting up and down using a single channel pipette (100-1,000 µL).
  11. Seed the RPE cell suspension of each eye globe into three wells of a 24-well cell culture plate and fill them up to 1 mL with DMEM/F12 supplemented with FBS, Pen/Strep, and AmphoB.
  12. Maintain the RPE cell cultures at 37 °C in a humidified atmosphere of 95% air and 5% CO2 until confluence is reached. Change the cell culture medium twice a week.

2. Electroporation of primary human RPE cells

  1. Preparation of the SB100X transposase/PEDF transposon plasmid mixture
    1. Purify the SB100X transposase and PEDF transposon plasmid DNA using customary plasmid purification kits, which are identified to be suitable for the use in applications such as transfection, according to the protocol of the manufacturer.
    2. Quantify the plasmid DNA contents using a microvolume spectrophotometer and adjust them to a concentration of 250 ng/µL with 10 mM Tris-HCl (pH 8.5).
    3. Mix one portion of 250 ng/µL SB100X transposase plasmid DNA (e.g., 2.5 µL) with 16 portions of 250 ng/µL PEDF transposon plasmid DNA (e.g., 40 µL). Residual plasmid mixture can be stored at -20 °C.
      ​NOTE: Multiple repeated freezing and thawing cycles of the plasmid mixture should be avoided.
    4. Place 2 µL of the SB100X transposase/PEDF transposon plasmid mixture, containing 29.4 ng of SB100X transposase plasmid and 470.6 ng of PEDF transposon plasmid, in a sterile 1.5 mL safe-lock microcentrifuge tube. Keep on ice until mixed with cells.
  2. Set-up of the capillary transfection system
    NOTE: Electroporation of primary human RPE cells has been performed via a capillary transfection system using the 10 µL kit according to the manufacturer's protocol. The system comprises the transfection device, the transfection pipette, and the pipette station. The kit contains 10 µL transfection tips, buffer tubes, electrolytic buffer E (buffer E), and resuspension buffer R (buffer R).
    1. Connect the pipette station to the transfection device.
    2. Fill a buffer tube with 3 mL of buffer E and insert it into the pipette station until a click sound is heard.
      NOTE: Ensure that the side electrode of the buffer tube is connected to the side ball plunger of the pipette station.
    3. For the electroporation of primary human RPE cells, set the following pulse conditions on the transfection device: 1,100 V (pulse voltage), 20 ms (pulse width), two pulses (pulse number).
  3. Preparation of the cultivated primary human RPE cells
    1. Document shape and morphology of the primary RPE cell cultures via phase contrast microscopy. Take low magnification micrographs to demonstrate the growth of the RPE cells to a confluent and integrated monolayer as well as higher magnification micrographs to point out the typical cobblestone morphology of the RPE cells.
    2. Aspirate the cell culture medium and wash the cells twice with 1 mL buffered phosphate saline (PBS, pH 7.4).
    3. Trypsinize primary human RPE cells with 0.5 mL 0.05% trypsin-EDTA at 37 °C in a humidified atmosphere of 95% air and 5% CO2 for 7-15 min (maximum). Check the cell detachment microscopically.
    4. Stop trypsinization with 1 mL of DMEM/F12 supplemented with FBS. Take a 20 µL aliquot for cell counting using a hemocytometer. Centrifuge the RPE cell suspension at 106 x g for 10 min.
    5. Mix the 20 µL aliquot with 20 µL trypan blue solution. Pipette 10 µL in each half of the hemocytometer and count the cells under a phase contrast microscope.
    6. After centrifugation, resuspend the RPE cell pellet in 1 mL of PBS.
    7. Take 10,000-100,000 RPE cells per transfection reaction and centrifuge them at 106 x g for 10 min.
      ​NOTE: Beside the transfection reactions with electric field application and addition of plasmid DNA, each approach also includes two different control cultures: (1) without electric field application and without plasmid DNA; (2) with electric field application, but without plasmid DNA.
    8. Resuspend the cell pellet in 11 µL of buffer R and combine it with 2 µL of the SB100X transposase/PEDF transposon plasmid mixture (see step 2.1.4).
      ​NOTE: After resuspension in buffer R, the cells must be processed within 15 min to avoid a reduction in cell viability and transfection efficiency.
    9. Insert the head of the transfection pipette into the 10 µL transfection tip until the clamp fully picks up the mounting stem of the piston. Draw up the cell/plasmid solution into the transfection tip.
      NOTE: Avoid generation of air bubbles and their aspiration into the transfection tip.
    10. Provide 1 mL of DMEM/F12 supplemented with FBS, but without Pen/Strep and without AmphoB, into the required number of wells of a 24-well cell culture plate.
  4. Electroporation process
    1. Insert the transfection pipette into the buffer tube placed in the pipette station (see step 2.2.2) until a click sound is heard.
      ​NOTE: Ensure the metal head of the transfection pipette is connected to the ball plunger inside of the pipette station and to the buffer tube.
    2. Press Start on the touchscreen of the transfection device. Before application of the electric pulse, the device automatically checks whether the buffer tube and the transfection pipette are properly inserted. After delivery of the electric pulses, Complete is displayed on the touchscreen.
    3. Carefully remove the transfection pipette from the pipette station and immediately release the electroporated cells from the 10 µL transfection tip by pipetting the cell/plasmid solution into the prepared wells of the cell culture plate (see step 2.3.10).
    4. Maintain transfected RPE cell cultures at 37 °C in a humidified atmosphere of 95% air and 5% CO2. Add Pen/Strep and AmphoB with the first medium exchange 3 days after electroporation.

3. Analyses of transfected primary human RPE cells

  1. Sample preparation
    1. After a cultivation time of 3 weeks, ultimately incubate the RPE cell cultures in a defined volume of 1.0 mL DMEM/F12 supplemented with FBS, Pen/Strep, and AmphoB for a defined time of 24 h.
    2. Take the cell culture supernatants and store them at -20 °C until further near-time processing or at -80 °C for thermally unstable samples and long-term storage.
    3. Trypsinize transfected RPE cell cultures with 0.5 mL of 0.05% trypsin-EDTA at 37 °C in a humidified atmosphere of 95% air and 5% CO2 for 10 min.
    4. Stop trypsinization with 1 mL of DMEM/F12 supplemented with FBS. Take small aliquots for cell counting using a hemocytometer (see step 2.3.5). Centrifuge the RPE cell suspensions at 106 x g for 10 min.
    5. Store the RPE cell pellets at -80 °C until further processing.
  2. Evaluation of PEDF secretion by western blotting
    NOTE: For a qualitative assessment, cell culture supernatants (see step 3.1.2) are analyzed via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequent western blotting. Depending on the PEDF transposon plasmid DNA used, the supernatants have to be processed differently.
    1. Purification of His-tagged PEDF fusion proteins from cell culture supernatants
      1. Take 30 µL nickel-nitrilotriacetic acid (Ni-NTA) slurry per sample using a bevel-cut tip and pellet the Ni-NTA resin by centrifugation (2,660 x g for 30 s).
      2. Carefully resuspend the Ni-NTA resin with 200 µL of 1x incubation buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and pellet it by centrifugation (2,660 x g for 30 s).
      3. Repeat the previous step.
      4. Carefully resuspend the Ni-NTA resin with 40 µL 4x incubation buffer (200 mM NaH2PO4, 1.2 M NaCl, 40 mM imidazole, pH 8.0) per sample.
      5. Mix 900 µL of cell culture supernatant with 260 µL of 4x incubation buffer and 55 µL of pretreated Ni-NTA slurry (see step 3.2.1.4).
      6. Incubate the mixture on a rocking shaker at room temperature for 60 min.
      7. Pellet the Ni-NTA resin by centrifugation (2660 x g for 60 s).
      8. Carefully resuspend the Ni-NTA resin with 175 µL of 1x incubation buffer and pellet resin by centrifugation (2,660 x g for 60 s).
      9. Repeat the previous step.
      10. Carefully resuspend the Ni-NTA resin with 30 µL of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0) and incubate the mixture on a rocking shaker at room temperature for 20 min.
      11. Pellet the Ni-NTA resin by centrifugation (2,660 x g for 30 s).
      12. Carefully take the supernatant and mix it with 2x SDS sample buffer47.
      13. Heat the mixture at 95 °C for 5 min and separate the Ni-NTA purified proteins on a 10% SDS-polyacrylamide gel.
      14. Perform western blotting using anti-Penta-His antibodies (mouse monoclonal, 1:500) and horseradish peroxidase (HRP)-conjugated anti-mouse antibodies (rabbit polyclonal, 1:1,000) as previously described36,37.
    2. Direct analysis of non-tagged PEDF proteins
      1. Take 15 µL of cell culture supernatant and mix it with 2x SDS sample buffer47.
      2. Heat the mixture at 95 °C for 5 min and separate the proteins on a 10% SDS-polyacrylamide gel.
      3. Perform western blotting using anti-human PEDF antibodies (rabbit polyclonal, 1:4,000) and HRP-conjugated anti-rabbit antibodies (goat polyclonal, 1:2,000) as previously described38.
    3. Quantification of PEDF secretion by ELISA
      1. Analyze cell culture supernatants (see step 3.1.2) using a human PEDF ELISA kit according to the manufacturer's protocol.
      2. Relate the amount of secreted PEDF to the time and the cell number determined for each transfection reaction (see step 3.1.4).
    4. Analysis of PEDF gene expression in transfected RPE cells
      1. Isolate total RNA from the RPE cell pellets (see step 3.1.5) using a commercially available kit according to the manufacturer's protocol.
      2. Quantify RNA contents using a microvolume spectrophotometer.
      3. Carry out reverse transcription on 0.1 µg RNA using a reverse transcription system according to the manufacturer's protocol.
      4. Perform real-time qPCR as previously described38.
    5. Analysis of transgene insertion sites in transfected RPE cells
      1. Isolate genomic DNA from the RPE cell pellets (see step 3.1.5) using a commercially available kit according to the manufacturer's protocol.
      2. Quantify DNA contents using a microvolume spectrophotometer.
      3. Generate insertion site libraries using a computation-assisted hemi-specific PCR scheme as previously described38.
      4. Perform computational analysis as previously described38.

Access restricted. Please log in or start a trial to view this content.

Results

Cultivation and electroporation of primary human RPE cells
We have shown that seeding of a sufficient number of primary RPE cells of animal origin allows for the cultivation and growth to an integrated monolayer of pigmented, hexagonally shaped cells36,37,48. Their capability to form tight junctions, to exhibit phagocytic activity, and to express specific marker genes in vitr...

Access restricted. Please log in or start a trial to view this content.

Discussion

In our project, we aim for the non-viral production of genetically modified primary human RPE cells that continuously overexpress and secrete an effective factor in order to use the transfected cells as long-term therapeutic for the establishment and maintenance of a protective environment. We have established the introduction of the gene encoding PEDF, an ubiquitously expressed multi-functional protein with anti-angiogenic and neuroprotective functions. The protocol described here can be used to stably and reproducibly ...

Access restricted. Please log in or start a trial to view this content.

Disclosures

Zoltán Ivics and Zsuzsanna Izsvák are inventors on several patents on SB transposon technology

Acknowledgements

This work was supported by the European Union's Seventh Framework Programme for research, technological development and demonstration, grant agreement no. 305134. Zsuzsanna Izsvák was funded by the European Research Council, ERC Advanced (ERC-2011-ADG 294742). The authors would like to thank Anna Dobias and Antje Schiefer (Department of Ophthalmology, University Hospital RWTH Aachen) for excellent technical support, and the Aachen Cornea Bank (Department of Ophthalmology, University Hospital RWTH Aachen) for providing the human donor eyes.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Isolation of primary human RPE cells
24-Well Cell Culture PlateEppendorf, Hamburg, Germany0030722019
Amphotericin B [250 µg/mL] (AmphoB)Merck, Darmstadt, GermanyA2942
Colibri ForcepsGeuder, Heidelberg, GermanyG-18950
Curved Iris Forceps Geuder, Heidelberg, GermanyG-18856
Disposable Scalpel (No. 11)Feather, Osaka, Japan
Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 Nutrient Mixture (DMEM/F12)PAN-Biotech, Aidenbach, GermanyP04-41150
Extra Fine Pointed Eye Scissor Geuder, Heidelberg, GermanyG-19405
Fetal Bovine Serum [0.2 µm Sterile Filtered] (FBS)PAN-Biotech, Aidenbach, GermanyP40-37500
Glass Pasteur PipettesBrand, Wertheim, Germany747715
Penicillin [10,000 units/mL] and Streptomycin [10 mg/mL] (Pen/Strep)Merck, Darmstadt, GermanyP0781
Pipette Tips (1000 µL)Starlab, Hamburg, Germany
Single Channel Pipette (100-1000 µL)Eppendorf, Hamburg, Germany
Sterile DrapeLohmann & Rauscher, Rengsdorf, Germany
Sterile Gauze Compress Fink-Walter, Merchweiler, Germany321063
Sterile GlovesSempermed, Wien, Austria
Sterile Petri Dish (Falcon 60 mm x 15 mm)Corning, Corning, NY351007
Sterile Surgical GownHalyard Health, Alpharetta, GA
Straight Iris Forceps Geuder, Heidelberg, GermanyG-18855
Electroporation of primary human RPE cells
10 mM Tris-HCl (pH 8.5)
12-Well Cell Culture PlateThermo Fisher Scientific, Waltham, MA150628
24-Well Cell Culture PlateEppendorf, Hamburg, Germany0030722019
Amphotericin B [250 µg/mL] (AmphoB)Merck, Darmstadt, GermanyA2942
Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 Nutrient Mixture (DMEM/F12)PAN-Biotech, Aidenbach, GermanyP04-41150
Safe-Lock Microcentrifuge Tubes (1.5 mL)Eppendorf, Hamburg, Germany
Fetal Bovine Serum [0.2 µm Sterile Filtered] (FBS)PAN-Biotech, Aidenbach, GermanyP40-37500
Inverted MicroscopeLeica Mikrosysteme, Wetzlar, GermanyLeica DMi8
Microvolume Spectrophotometer (NanoDrop Spectrophotometer)Thermo Fisher Scientific, Waltham, MA
Capillary Transfection System (Neon Transfection System)Thermo Fisher Scientific, Waltham, MAMPK5000
Neon Transfection System 10 µL KitThermo Fisher Scientific, Waltham, MAMPK1096
Hemocytometer (Neubauer Chamber)Paul Marienfeld, Lauda-Königshofen, Germany0640110
PBS Dulbecco w/o Ca2+ w/o Mg2+Biochrom, Berlin, GermanyL182-50
Penicillin [10,000 units/mL] and Streptomycin [10 mg/mL] (Pen/Strep)Merck, Darmstadt, GermanyP0781
Pipette Tips (10 µL)Starlab, Hamburg, Germany
Pipette Tips (1000 µL)Starlab, Hamburg, Germany
Pipette Tips (200 µL)Starlab, Hamburg, Germany
Plasmid Maxi KitQiagen, Hilden, Germany12163
Single Channel Pipette (0.1-10 µL)Eppendorf, Hamburg, Germany
Single Channel Pipette (100-1000 µL)Eppendorf, Hamburg, Germany
Single Channel Pipette (10-200 µL)Eppendorf, Hamburg, Germany
Trypan Blue SolutionMerck, Darmstadt, GermanyT8154
Trypsin-EDTA (0,05 %)Thermo Fisher Scientific, Waltham, MA25300054
Analyses of transfected primary human RPE cells
10% SDS-Polyacrylamide Gel
1x Incubation Buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0)
2x SDS Sample Buffer
4x Incubation Buffer (200 mM NaH2PO4, 1.2 M NaCl, 40 mM imidazole, pH 8.0)
Amersham Protran Supported 0.2 µm Nitrocellulose Blotting MembraneCytiva, Marlborough, MA10600015
Amphotericin B [250 µg/mL] (AmphoB)Merck, Darmstadt, GermanyA2942
Anti-PEDF Antibodies (Rabbit Polyclonal)BioProducts, Middletown, MDAB-PEDF1
Anti-Penta-His Antibodies (Mouse Monoclonal)Qiagen, Hilden, Germany34660
Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 Nutrient Mixture (DMEM/F12)PAN-Biotech, Aidenbach, GermanyP04-41150
Elution Buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0) 
Fetal Bovine Serum [0.2 µm Sterile Filtered] (FBS)PAN-Biotech, Aidenbach, GermanyP40-37500
Hemocytometer (Neubauer Chamber)Paul Marienfeld, Lauda-Königshofen, Germany0640110
Horseradish Peroxidase-Conjugated Anti-Mouse Antibodies (Rabbit Polyclonal)Agilent Dako, Santa Clara, CAP0260
Horseradish Peroxidase-Conjugated Anti-Rabbit Antibodies (Goat Polyclonal)Abcam, Cambridge, United Kingdomab6721
Human PEDF ELISA Kit BioProducts, Middletown, MDPED613
LAS-3000 Imaging SystemFujifilm, Minato, Japan
LightCycler 1.2 InstrumentRoche Life Science, Penzberg, Germany
LightCycler FastStart DNA Master SYBR Green IRoche Life Science, Penzberg, Germany12239264001
LightCycler Capillaries (20 μl)Roche Life Science, Penzberg, Germany4929292001
Microvolume Spectrophotometer (NanoDrop Spectrophotometer)Thermo Fisher Scientific, Waltham, MA
Mini-PROTEAN Tetra Cell Casting ModuleBio-Rad Laboratories, Feldkirchen, Germany1658015
Mini-PROTEAN Tetra Vertical Electrophoresis Cell for Mini Precast Gels, 4-gelBio-Rad Laboratories, Feldkirchen, Germany1658004
Ni-NTA SuperflowQiagen, Hilden, Germany30410
PageRuler Prestained Protein LadderThermo Fisher Scientific, Waltham, MA26616
Penicillin [10,000 units/mL] and Streptomycin [10 mg/mL] (Pen/Strep)Merck, Darmstadt, GermanyP0781
Pipette Tips (10 µL)Starlab, Hamburg, Germany
Pipette Tips (1000 µL)Starlab, Hamburg, Germany
Pipette Tips (200 µL)Starlab, Hamburg, Germany
PowerPac Basic Power SupplyBio-Rad Laboratories, Feldkirchen, Germany1645050
QIAamp DNA Mini KitQiagen, Hilden, Germany51304
Reverse Transcription System Promega, Madison, WIA3500
RNase-Free DNase SetQiagen, Hilden, Germany79254
RNeasy Mini Kit Qiagen, Hilden, Germany74104
Rocking ShakerCole-Parmer, Staffordshire, United KingdomSSM3
Safe-Lock Microcentrifuge Tubes (1.5 mL)Eppendorf, Hamburg, Germany
Safe-Lock Microcentrifuge Tubes (2.0 mL)Eppendorf, Hamburg, Germany
Single Channel Pipette (0.1-10 µL)Eppendorf, Hamburg, Germany
Single Channel Pipette (100-1000 µL)Eppendorf, Hamburg, Germany
Single Channel Pipette (10-200 µL)Eppendorf, Hamburg, Germany
Trans-Blot Turbo Transfer SystemBio-Rad Laboratories, Feldkirchen, Germany1704150
Trypan Blue SolutionMerck, Darmstadt, GermanyT8154
Trypsin-EDTA (0,05 %)Thermo Fisher Scientific, Waltham, MA25300054

References

  1. James, S. L., et al. national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 392 (10159), 1789-1858 (2018).
  2. Wong, W. L., et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health. 2 (2), 106-116 (2014).
  3. Strauss, O. The retinal pigment epithelium in visual function. Physiological Reviews. 85 (3), 845-881 (2005).
  4. Chan, C. K., et al. Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization. Laboratory Investigation. 85 (6), 721-733 (2005).
  5. Gao, G., et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Letters. 489 (2-3), 270-276 (2001).
  6. Bhutto, I. A., et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Experimental Eye Research. 82 (1), 99-110 (2006).
  7. Holekamp, N. M., Bouck, N., Volpert, O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. American Journal of Ophthalmology. 134 (2), 220-227 (2002).
  8. Kolomeyer, A. M., Sugino, I. K., Zarbin, M. A. Characterization of conditioned media collected from aged versus young human eye cups. Investigative Ophthalmology & Visual Science. 52 (8), 5963-5972 (2011).
  9. Li, X., et al. The significance of the increased expression of phosphorylated MeCP2 in the membranes from patients with proliferative diabetic retinopathy. Scientific Reports. 6, 32850(2016).
  10. Mohan, N., Monickaraj, F., Balasubramanyam, M., Rema, M., Mohan, V. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. Journal of Diabetes and its Complications. 26 (5), 435-441 (2012).
  11. Empeslidis, T., et al. How successful is switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A systematic overview. Advances in Therapy. 36 (7), 1532-1548 (2019).
  12. Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., Hawkins, B. S. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. 3, (2019).
  13. Dugel, P. U., et al. phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 127 (1), 72-84 (2020).
  14. Falavarjani, K. G., Nguyen, Q. D. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 27 (7), 787-794 (2013).
  15. Jaffe, D. H., Chan, W., Bezlyak, V., Skelly, A. The economic and humanistic burden of patients in receipt of current available therapies for nAMD. Journal of Comparative Effectiveness Research. 7 (11), 1125-1132 (2018).
  16. Eghoj, M. S., Sorensen, T. L. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. British Journal of Ophthalmology. 96 (1), 21-23 (2012).
  17. Forooghian, F., Cukras, C., Meyerle, C. B., Chew, E. Y., Wong, W. T. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina - The Journal of Retinal and Vitreous Diseases. 29 (6), 723-731 (2009).
  18. Otsuji, T., et al. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clinical Ophthalmology. 7, 1487-1490 (2013).
  19. Zuber-Laskawiec, K., Kubicka-Trzaska, A., Karska-Basta, I., Pociej-Marciak, W., Romanowska-Dixon, B. Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration. Journal of Physiology and Pharmacology. 70 (5), (2019).
  20. Campochiaro, P. A., et al. Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration (GEM) study. Human Gene Therapy. 28 (1), 99-111 (2017).
  21. Constable, I. J., et al. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine. 14, 168-175 (2016).
  22. Rakoczy, E. P., et al. Three-year follow-up of phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age-related macular degeneration. American Journal of Ophthalmology. 204, 113-123 (2019).
  23. Kumar-Singh, R. The role of complement membrane attack complex in dry and wet AMD - from hypothesis to clinical trials. Experimental Eye Research. 184, 266-277 (2019).
  24. Campochiaro, P. A., et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Human Gene Therapy. 17 (2), 167-176 (2006).
  25. Campochiaro, P. A. Gene transfer for neovascular age-related macular degeneration. Human Gene Therapy. 22 (5), 523-529 (2011).
  26. Ahi, Y. S., Bangari, D. S., Mittal, S. K. Adenoviral vector immunity: its implications and circumvention strategies. Current Gene Therapy. 11 (4), 307-320 (2011).
  27. Hacein-Bey-Abina, S., et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine. 363 (4), 355-364 (2010).
  28. Howe, S. J., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. Journal of Clinical Investigation. 118 (9), 3143-3150 (2008).
  29. Stieger, K., et al. Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Molecular Therapy. 16 (5), 916-923 (2008).
  30. Tornabene, P., Trapani, I. Can adeno-associated viral vectors deliver effectively large genes. Human Gene Therapy. 31 (1-2), 47-56 (2020).
  31. Ayuso, E. Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome. Molecular Therapy - Methods & Clinical Development. 3, 15049(2016).
  32. van der Loo, J. C., Wright, J. F. Progress and challenges in viral vector manufacturing. Human Molecular Genetics. 25, 42-52 (2016).
  33. Ivics, Z., Hackett, P. B., Plasterk, R. H., Izsvak, Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 91 (4), 501-510 (1997).
  34. Mates, L., et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nature Genetics. 41 (6), 753-761 (2009).
  35. Izsvak, Z., Hackett, P. B., Cooper, L. J., Ivics, Z. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays. 32 (9), 756-767 (2010).
  36. Thumann, G., et al. High efficiency non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Therapy. 17 (2), 181-189 (2010).
  37. Johnen, S., et al. Sleeping Beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. Investigative Ophthalmology & Visual Science. 53 (8), 4787-4796 (2012).
  38. Thumann, G., et al. Engineering of PEDF-expressing primary pigment epithelial cells by the SB transposon system delivered by pFAR4 plasmids. Molecular Therapy - Nucleic Acids. 6, 302-314 (2017).
  39. Abdul Halim, N. S., Fakiruddin, K. S., Ali, S. A., Yahaya, B. H. A comparative study of non-viral gene delivery techniques to human adipose-derived mesenchymal stem cell. International Journal of Molecular Sciences. 15 (9), 15044-15060 (2014).
  40. Ahlemeyer, B., Vogt, J. F., Michel, V., Hahn-Kohlberger, P., Baumgart-Vogt, E. Microporation is an efficient method for siRNA-induced knockdown of PEX5 in HepG2 cells: evaluation of the transfection efficiency, the PEX5 mRNA and protein levels and induction of peroxisomal deficiency. Histochemistry and Cell Biology. 142 (5), 577-591 (2014).
  41. May, R. D., et al. Efficient nonviral transfection of primary intervertebral disc cells by electroporation for tissue engineering application. Tissue Engineering Part C - Methods. 23 (1), 30-37 (2017).
  42. Kim, J. A., et al. A novel electroporation method using a capillary and wire-type electrode. Biosensors & Bioelectronics. 23 (9), 1353-1360 (2008).
  43. Johnen, S., et al. Antiangiogenic and neurogenic activities of Sleeping Beauty-mediated PEDF-transfected RPE cells in vitro and in vivo. Biomed Research International. 2015, 863845(2015).
  44. Kuerten, D., et al. Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model. Graefes Archive for Clinical and Experimental Ophthalmology. 253 (7), 1061-1069 (2015).
  45. Garcia-Garcia, L., et al. Long-term PEDF release in rat iris and retinal epithelial cells after Sleeping Beauty transposon-mediated gene delivery. Molecular Therapy - Nucleic Acids. 9, 1-11 (2017).
  46. Hernandez, M., et al. Preclinical evaluation of a cell-based gene therapy using the Sleeping Beauty transposon system in choroidal neovascularization. Molecular Therapy - Methods & Clinical Development. 15, 403-417 (2019).
  47. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227 (5259), 680-685 (1970).
  48. Johnen, S., et al. Presence of xenogenic mouse RNA in RPE and IPE cells cultured on mitotically inhibited 3T3 fibroblasts. Investigative Ophthalmology & Visual Science. 52 (5), 2817-2824 (2011).
  49. Gogol-Doring, A., et al. Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4(+) T cells. Molecular Therapy. 24 (3), 592-606 (2016).
  50. Holstein, M., et al. Efficient non-viral gene delivery into human hematopoietic stem cells by minicircle Sleeping Beauty transposon vectors. Molecular Therapy. 26 (4), 1137-1153 (2018).
  51. Moldt, B., et al. Comparative genomic integration profiling of Sleeping Beauty transposons mobilized with high efficacy from integrase-defective lentiviral vectors in primary human cells. Molecular Therapy. 19 (8), 1499-1510 (2011).
  52. Yant, S. R., et al. High-resolution genome-wide mapping of transposon integration in mammals. Molecular and Cellular Biology. 25 (6), 2085-2094 (2005).
  53. Grabundzija, I., et al. Comparative analysis of transposable element vector systems in human cells. Molecular Therapy. 18 (6), 1200-1209 (2010).
  54. Dunn, K. C., Aotaki-Keen, A. E., Putkey, F. R., Hjelmeland, L. M. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Experimental Eye Research. 62 (2), 155-169 (1996).
  55. Chang, L., et al. Micro-/nanoscale electroporation. Lab on a Chip. 16 (21), 4047-4062 (2016).
  56. Shi, J., et al. A review on electroporation-based intracellular delivery. Molecules. 23 (11), (2018).
  57. Johnen, S., et al. Endogenic regulation of proliferation and zinc transporters by pigment epithelial cells nonvirally transfected with PEDF. Investigative Ophthalmology & Visual Science. 52 (8), 5400-5407 (2011).
  58. Pastor, M., et al. The antibiotic-free pFAR4 vector paired with the Sleeping Beauty transposon system mediates efficient transgene delivery in human cells. Molecular Therapy - Nucleic Acids. 11, 57-67 (2018).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

PEDF Gene ExpressionCapillary ElectroporationPlasmid DNA PreparationWestern Blot AnalysisELISA QuantificationNickel NTA PurificationStable Transgene Integration
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.